Introduction
Alcohol and substance use disorders represent some of the most challenging conditions in mental health and addiction medicine. While pharmacotherapy and cognitive behavioural interventions form the backbone of evidence-based treatment, hypnotherapy has been explored as a complementary approach for several decades. This article evaluates the current state of research on hypnotherapy for alcohol and substance use disorders, examining both its potential benefits and its limitations.
Historical Context
The use of hypnosis in addiction treatment dates back to the early 20th century, with early practitioners reporting success in treating alcohol dependence through direct suggestions for aversion and abstinence. The mid-20th century saw a decline in interest as psychopharmacological approaches gained prominence, but recent decades have witnessed a resurgence of research interest, driven in part by the limitations of existing treatments and growing patient demand for complementary therapies.
Mechanisms of Action
Hypnotherapy for substance use disorders typically employs several therapeutic mechanisms. Aversion techniques aim to create negative associations with the substance — for example, suggesting that the taste or smell of alcohol will become nauseating. Ego-strengthening suggestions target underlying self-esteem deficits and enhance the patient’s sense of agency and self-control. Cognitive restructuring through hypnosis attempts to modify maladaptive beliefs about substance use, while relaxation and stress-reduction techniques address the anxiety and tension that often trigger relapse. Post-hypnotic cues can also be established to activate coping responses automatically when cravings arise.
Alcohol Use Disorder: The Evidence
A 2020 systematic review in Substance Abuse Treatment, Prevention, and Policy identified 17 studies examining hypnosis for alcohol use disorder. The review noted that while many early studies reported positive outcomes, the methodological quality was generally poor. Only five studies met criteria for moderate to high quality, and of these, three reported significant reductions in alcohol consumption among hypnosis groups compared to controls. A 2021 randomised trial from New Zealand involving 84 participants with alcohol dependence compared hypnosis-enhanced CBT to standard CBT. At six-month follow-up, the hypnosis group reported 35% fewer heavy drinking days and significantly lower craving scores.
One area where hypnosis shows particular promise is in treating co-morbid anxiety and alcohol use. A 2022 Australian study found that participants receiving hypnosis for alcohol dependence who also had elevated anxiety scores showed greater reductions in alcohol consumption than those without anxiety, suggesting that hypnosis may be especially effective for individuals whose substance use is driven by stress and tension.
Substance Use Disorders: Broader Evidence
The evidence for hypnotherapy in illicit substance use disorders is more limited. A 2019 review in the American Journal of Clinical Hypnosis covered studies on opioid, cocaine, and cannabis use disorders, but identified only eight randomised trials meeting basic methodological standards. Results were mixed. For opioid use disorder, one small trial found that hypnosis reduced withdrawal symptoms during medically assisted detoxification, but did not significantly affect relapse rates. For cocaine use, two trials showed reductions in craving intensity but not in actual drug use. For cannabis, the evidence is too sparse to draw meaningful conclusions.
A 2023 pilot study from the United Kingdom examined hypnosis as an adjunct to methadone maintenance treatment for opioid dependence. Participants receiving hypnosis reported lower craving scores and improved treatment retention, though the small sample size (n = 36) and lack of long-term follow-up limit generalisability.
Methodological Challenges
Research in this area faces significant hurdles. The heterogeneity of hypnotic interventions makes comparison across studies difficult. Additionally, substance use disorders are complex biopsychosocial conditions, and isolating the specific contribution of hypnosis from concurrent treatments is challenging. Relapse rates are high across all addiction treatments, and studies with longer follow-up periods tend to show attenuation of treatment effects. The potential for hypnotic suggestibility to vary between individuals also complicates treatment response prediction and trial design.
Clinical Considerations
Practitioners using hypnosis for substance use disorders should be appropriately qualified in both clinical hypnosis and addiction treatment. The Australian Psychological Society notes that hypnosis may be a useful adjunctive technique for motivated patients but should not replace established treatments such as pharmacotherapy (e.g. naltrexone for alcohol, buprenorphine for opioids) or evidence-based psychotherapies. Integration with multidisciplinary treatment approaches is essential, and patients should be carefully screened for suitability, as those with severe cognitive impairment or active psychosis may not be appropriate candidates.
Conclusion
Hypnotherapy for alcohol and substance use disorders remains a promising but under-researched area. The strongest evidence exists for alcohol use disorder, particularly when hypnosis is combined with CBT and addresses co-morbid anxiety. For other substances, the evidence is preliminary and inconclusive. Larger, methodologically rigorous trials with standardised protocols and longer follow-up periods are urgently needed to establish the place of hypnotherapy within addiction treatment pathways.